ArticleChemistry, an Asian journal2026
Synthesis, Characterization, Crystal Structure and Anti-TB and Anticancer Applications of Redox Active Phenanthroline Derivatized With Methyl-, Ethyl-, and Benzyl Carbazates.
Article in Chemistry, an Asian journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Developing new molecules for treating bacterial infections and cancer disease is an important area of exploration as both types of cells often develop resistance to known drug candidates. Synthesis, structural characterization, and bioactivity of heterocyclic compounds 6-[2-(benzyloxycarbonyl)diazen-1-yl]-1-10-phenanthroline-5-one (BCDPO) along with 6-[2-(ethoxycarbonyl)diazen-1-yl]-1-10-phenanthroline-5-one (ECDPO) and 6-[2-(methoxycarbonyl)diazen-1-yl]-1-10-phenanthroline-5-one (MCDPO), which are 1,10-phenanthroline-5,6-dione (PD) derivatized with benzyl carbazate (BC), ethyl carbazate (EC), and methyl carbazate (MC), respectively, are studied. The BCDPO crystallized in triclinic system P-1 space group, the supramolecular BCDPO arrays stabilized involving noncovalent O···H and N···H hydrogen bond interactions as well as π-π stacking aromatic interactions. Redox properties studied through cyclic voltammetry and spectroelectrochemistry. The benzyl analog showed better anti-tuberculosis (TB) activity than the methyl and ethyl analogs. The BCDPO shows good minimum inhibitory concentration (MIC) against Mycobacterium tuberculosis (Mtb), which is equivalent to clinically used rifampicin but better than the one of the clinically used drug candidates ethambutol. These compounds exhibit promising anticancer activity against the murine-triple-negative breast cancer (4T1), human breast cancer (MCF-7), and human prostate cancer (PC-3) cancer cell lines. Fluorescence confocal imaging and flow cytometry studies are performed to monitor the compound-induced reactive oxygen species (ROS) generation, nuclear fragmentation, and apoptosis in cancer cell death. The carbazate functionalized phenanthroline derivatives developed are showing promising anti-TB and anticancer activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.